(NewsDirect)
In the interview,Dr. Michael Pishvaian discussed the trial's potential impact onthe oncology community as well as how pancreatic cancer patients aretreated. Dr. Pishvaian’s interview with OncologyTube is featured here .
Recently RenovoRx( RNXT ) announcedinterim data in the Phase 3 open-label TIGeR-PaC clinical trialinvestigating the company's first product candidate, RenovoGem, asa potential treatment option in locally advanced pancreatic cancer(LAPC). The interim analysis suggests a 6-month potential improvementin median overall survival with RenovoGem. The study comparestreatment with RenovoTAMP versus standard-of-care systemic intravenousadministration of gemcitabine and nab-paclitaxel, which has aseven-week survival benefit and a $1 billion addressable market.
About LocallyAdvanced Pancreatic Cancer (LAPC)
According to American Cancer Society’sCancer Facts & Figures 2023, pancreatic cancer has a 5-yearcombined overall survival rate of 12% (Stages I-IV) and is on track tobe the second leading cause of cancer-related deaths before 2030. LAPCis diagnosed when the disease has not spread far beyond pancreas,however, has advanced to the point where it cannot be surgicallyremoved. LAPC is typically associated with patients in stage 3 of thedisease as determined by the TNM (tumor, nodes and metastasis) gradingsystem.
AboutRenovoGem
RenovoGem™ is the first drug-device combination productcandidate that utilizes the RenovoTAMP ® therapy platformvia pressure-mediated delivery technology to deliver gemcitabine, anFDA-approved chemotherapy, locally across the arterial wall to bathetumor tissue in the chemotherapy. RenovoGem is currently beingevaluated in the Phase III TIGeR-PaC clinical trial study in LocallyAdvanced Pancreatic Cancer (LAPC) patients. The Company plans toinvestigate RenovoGem in extrahepatic Cholangiocarcinoma (eCCA) in aclinical trial, which is anticipated to begin in the first half of2023.
AboutRenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company with avision to disrupt the current paradigm of cancer treatment. Ourmission is to lead a revolution in oncology therapy by delivering itsinnovative and targeted intra-arterial (IA) delivery of chemotherapydirectly to solid tumors. The proprietary RenovoRx Trans-ArterialMicro-Perfusion (RenovoTAMP ® ) therapy platform aims toavoid the harsh side effects typical of the current standard of care,or systemic delivery methods, thus improving patient well-being and,potentially extension of life, so more time may be enjoyed with lovedones. RenovoTAMP utilizes approved chemotherapeutics with validatedmechanisms of action and well-established safety and clinical use,with the goal of improving their safety, tolerance, and widening theirtherapeutic window by providing more targeted delivery at the locationof the tumor tissue. RenovoRx’s lead product candidate,RenovoGem TM , is a combination of gemcitabine and itspatented delivery system, RenovoCath ® , and is regulated bythe FDA as a novel oncology drug product to treat unresectable locallyadvanced pancreatic cancer (LAPC). RenovoGem is currently beingstudied in the Phase III TIGeR-PaC clinical trial for the treatment ofLAPC.
RenovoRx’s patent portfolio for its therapy platform andproduct candidates includes eight issued U.S. patents, one issuedEuropean patent, and several additional patents pending in the US, EUand Asia. RenovoRx has been granted Orphan Drug Designation forintra-arterial delivery of gemcitabine for the treatment of bothpancreatic cancer and bile duct cancer (cholangiocarcinoma).
Originally publishedon TalkMarkets
RenovoRX'sLatest Innovative Technology Creates New Hope For ChemotherapyPatients
More By TalkMarketsNewswire:
SurgePaysPasses 150,000 Mobile Broadband Subscribers
SurgePaysAnnounces the Acquisition of Torch Wireless
ContactDetails
TalkMarkets
+1 732-325-3037
Copyright (c) 2023 TheNewswire - All rights reserved.